Heart failure is a serious chronic progressive heart disease with high morbidity and mortality. Sotagliflozin is a novel sodium and glucose cotransporter-1/2 inhibitor, which can inhibit glucose absorption in the digestive tract and renal tubules at the same time. A number of studies have confirmed that sotagliflozin is not only as effective as sodium-glucose co-transporter-2 inhibitors in reducing cardiovascular mortality and rehospitalization rate in patients with heart failure, but also can reduce the incidence of stroke and myocardial infarction in patients with heart failure. This article reviews the mechanism and research progress of sotagliflozin in the treatment of heart failure, in order to provide help for the clinical treatment of patients with heart failure in the future.